---
schema_version: "secwatch.filing_event.v1"
accession: "0001171520-22-000305"
form_type: "8-K"
ticker: "CLPT"
cik: "0001285550"
company_name: "ClearPoint Neuro, Inc."
filed_at: "2022-05-11T23:59:59+00:00"
generated_at: "2026-06-25T20:35:06.133676+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ClearPoint Neuro Q1 revenue $5.0M, up 25% YoY; raises FY2022 guidance to $21-22M

## Summary
- Record quarterly revenue of $5.0M, a 25% increase vs Q1 2021.
- Biologics and drug delivery revenue $2.2M (+30% YoY); functional neurosurgery revenue $2.2M (+17%).
- Operating expenses $7.1M, up from $4.8M in Q1 2021, driven by headcount and R&D.
- Cash position $49.7M at March 31, 2022 vs $54.1M at year-end 2021.
- Raised FY2022 revenue guidance to $21.0-22.0M, representing 30-35% growth.

## SEC filing metadata
- accession: 0001171520-22-000305
- form_type: 8-K
- ticker: CLPT
- cik: 0001285550
- company_name: ClearPoint Neuro, Inc.
- filed_at: 2022-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285550/000117152022000305/0001171520-22-000305-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285550/000117152022000305/eps10228_clpt.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171520-22-000305
- JSON: https://secwatch.observer/filing/0001171520-22-000305.json
- Plain text: https://secwatch.observer/filing/0001171520-22-000305.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.